Figure 6
Anti-A20 Id + CpG combination therapy can mediate tumor destruction at local and distant tumor sites. (A) Balb/c mice were inoculated with 107 A20 cells subcutaneously on2 different locations on the abdomen. Therapy was administered when tumors were 1 cm2 (day 0). Anti-A20 Id mAb was administered intraperitoneally on day 0, and CpG was administered intratumorally on days 2, 3, 4, 6, and 8 in only a single tumor (P < .001). Each line is representative of a group consisting of 10 mice. (B) Photographs were taken of mice shown (on day 15) in panel A demonstrating that anti-A20 Id mAb + CpG combination therapy was superior to CpG or antibody alone in inhibiting the growth of both treated and untreated A20 tumors. ↑ points to the treated tumor.
